Informações de VolitionRX Ltd

Mais detalhes de VolitionRX Ltd Empresa

VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.



Código da empresaVNRX

Nome da EmpresaVolitionRX Ltd

Data de listagemFeb 06, 2015

CEODr. Jasmine Kway

Número de funcionários85

Tipo de títulosOrdinary Share

Fim do ano fiscalFeb 06

Endereço1489 West Warm Springs Road

CidadeHENDERSON

Bolsa de valoresNYSE American Consolidated

PaísUnited States of America

Código postal89014

Telefone17024251561

Sitehttps://volition.com/

Código da empresaVNRX

Data de listagemFeb 06, 2015

CEODr. Jasmine Kway

Executivos da empresa VolitionRX Ltd



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Guy Archibald Innes

Independent Director

2.98M

+3.33%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

2.29M

+5.05%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

444.76K

-1.30%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

388.15K

+7.22%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

325.40K

-1.41%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

203.61K

+6.54%

Dr. Alan Colman, Ph.D.

Independent Director

203.55K

-10.28%

Mr. Gael Forterre

Chief Commercial Officer

153.78K

-1.13%

Mr. Nicholas Plummer

Group General Counsel

150.58K

-3.61%

Dr. Andrew Retter

Chief Medical Officer

146.57K

-3.04%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Guy Archibald Innes

Independent Director

2.98M

+3.33%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

2.29M

+5.05%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

444.76K

-1.30%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

388.15K

+7.22%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

325.40K

-1.41%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

203.61K

+6.54%

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: há 10 horas

Investidores

Tipos de investidores

Investidores

Proporção

Cotterford Co., Ltd.

10.39%

Lagoda Investment Management, L.P.

10.13%

Armistice Capital LLC

7.35%

Innes (Guy Archibald)

2.58%

Reynolds (Cameron John)

1.98%

Outro

67.57%

Investidores

Proporção

Cotterford Co., Ltd.

10.39%

Lagoda Investment Management, L.P.

10.13%

Armistice Capital LLC

7.35%

Innes (Guy Archibald)

2.58%

Reynolds (Cameron John)

1.98%

Outro

67.57%

Tipos de investidores

Investidores

Proporção

Investment Advisor

12.24%

Corporation

11.26%

Hedge Fund

7.54%

Individual Investor

6.97%

Investment Advisor/Hedge Fund

0.97%

Research Firm

0.04%

Outro

60.98%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

57

24.01M

20.78%

+2.74M

2025Q2

78

41.39M

40.30%

+860.69K

2025Q1

83

44.42M

46.85%

+2.70M

2024Q4

82

41.53M

44.82%

+1.50M

2024Q3

82

38.59M

41.90%

+9.42M

2024Q2

82

28.77M

32.86%

+105.49K

2024Q1

84

28.22M

34.52%

+1.47M

2023Q4

87

26.17M

37.10%

+183.39K

2023Q3

91

25.37M

36.48%

-477.38K

2023Q2

98

25.03M

37.36%

-1.92M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Cotterford Co., Ltd.

12.01M

11.16%

--

Apr 25, 2025

Lagoda Investment Management, L.P.

11.71M

10.88%

+1.51M

+14.82%

Jun 30, 2025

Armistice Capital LLC

8.49M

7.89%

+286.64K

+3.49%

Jun 30, 2025

Innes (Guy Archibald)

2.88M

2.68%

+78.13K

+2.78%

Aug 05, 2025

Reynolds (Cameron John)

2.18M

2.02%

+15.00K

+0.69%

Sep 12, 2025

The Vanguard Group, Inc.

1.62M

1.51%

+918.67K

+130.11%

Jun 30, 2025

Concord International Inc.

1.01M

0.94%

--

Apr 25, 2025

Geode Capital Management, L.L.C.

764.89K

0.71%

+2.94K

+0.39%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

445.19K

0.41%

--

Jun 30, 2025

Micallef (Jacob Vincent)

450.61K

0.42%

-5.57K

-1.22%

Sep 28, 2025

Ver Mais

ETFs Relacionados



Atualizado em: dom, 2 de nov

Nome

Proporção

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados